Citations

Clear

124 citation(s) found for "Storm, A".

An Unusual Presentation of Pediatric Gastrointestinal Stromal Tumor
Cárdenas, María C. , Hamel, Benjamin , Weckwerth, Jody , Potter, Dean, Bofill-Garcia, Aliana M., Schwartz, Jonathan , Hassan, Sara , Gonzalez, Michelle , Cardenas, Maria Camila, Hassan, Sara, Storm, Andrew C.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | July 12, 2023 | Volume: 77 | Issue: 5 | Pages: No page available

10.1097/mpg.0000000000003888 | PMID 37434284 Get It

Marginal Ulcers after Roux-en-Y Gastric Bypass: Etiology, Diagnosis, and Management
Salame, Marita , Belluzzi, Amanda, Al-Kordi, Mohammad, Jawhar, Noura , Storm, Andrew C. , Dayyeh, Barham K. Abu , Ghanem, Omar M.

Mayo Clinic

Journal of Clinical Medicine | June 28, 2023 | Volume: 12 | Issue: 13 | Pages: 4336

10.3390/jcm12134336 | PMID 37445371 Get It

Marginal ulcer (MU) is a potential complication following Roux-en-Y gastric bypass (RYGB), with a mean prevalence of 4.6%. Early identification and prompt intervention are crucial to mitigating further complications. The pathophysiology of MU is complex and involves multiple factors, including smoking, Helicobacter pylori infection, non-steroidal anti-inflammatory drug (NSAID) use, and larger pouch size. Patients with MU may experience acute or chronic abdominal pain. Rarely, they may present with a complication from the ulceration, such as bleeding, perforation, or strictures. Following diagnosis by endoscopy, management of MU typically involves modification of risk factors and medical therapy focused on proton pump inhibitors. In case of complicated ulcers, surgical intervention is often required for the repair of the perforation or resection of the stricture. For recurrent or recalcitrant ulcers, endoscopic coverage of the ulcer bed, resection of the anastomosis, and abdominal or thoracoscopic truncal vagotomy may be considered. This review aims at providing an overview of the etiology, diagnosis, and management of MU after RYGB.
Tubularization of the gastric pouch helps sustain weight loss after transoral outlet reduction for post-Roux-en-Y gastric bypass weight recurrence
Abboud, Donna Maria , Ghazi, Rabih , Brunaldi, Vitor , Gala, Khushboo , Baroud, Serge , Kerbage, Anthony , Abdul-Razzak, Farah, Annan, Karim Al , Rapaka, Babusai , Yao, Rebecca , AbdulRazzak, Farah, Al Annan, Karim, Vargas, Eric J , Storm, Andrew C , Abboud, Donna M , Vargas, Eric J. , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy International Open | June 26, 2023 | Volume: 11 | Issue: 09 | Pages: E829-E834

10.1055/a-2117-8113 | PMID 37719801 Get It

Abstract Background and study aims Traditional transoral outlet reduction (TORe) is a minimally invasive endoscopic approach focused on reducing the aperture of the gastrojejunal (GJ) anastomosis, while the tubular transoral outlet reduction (tTORe) consists of tabularization of the distal pouch utilizing an O-shape gastroplasty suturing pattern. The primary aim of this study was to compare short-term weight loss between TORe and tTORe. Patients and methods Retrospective analysis of a prospectively maintained database was conducted at a tertiary care bariatric center of excellence. The study included patients with history of Roux-en-Y gastric bypass (RYGB) who had an endoscopic revision by TORe or tTORe and had follow-up data in their electronic medical record. The primary outcome was percent total body weight loss (%TBWL). Results A total of 128 patients were included (tTORe=85, TORe=43). At 3 and 6 months, the tTORe and TORe cohorts presented similar %TBWL (3 months: 8.5±4.9 vs. 7.3±6.0, P = 0.27 and 6 months: 8.1±7.4 vs. 6.8±5.6, P = 0.44). At 9 months, there was a trend toward greater weight loss in the tTORe cohort (9.7±8.6% vs. 5.1±6.8%, P = 0.053). At 12 months, the %TBWL was significantly higher in the tubularization group compared to the standard group (8.2±10.8 vs. 2.3±7.3%, P = 0.01). Procedure time was significantly different between both groups (60.5 vs. 53.4 minutes, P = 0.03). The adverse events rate was similar between groups (8.2% vs. 7.0% for tTORe and TORe, respectively, P = 0.61). Conclusions The tTORe enhances efficacy and durability of the standard procedure without adding significant procedure-related risks.
Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure
Alkhatry, Maryam, Rapaka, Babusai , Maselli, Daniel B. , Abboud, Donna Maria , Brunaldi, Vitor , Mahmoud, Tala , Ghazi, Rabih , Razzak, Farah Abdul, Gala, Khushboo, Joudah, Imad, Housen, Fedaa, Qadi, Sana Al, Brunaldi, Vitor Ottoboni , Abdul Razzak, Farah, Vargas, Eric J , Storm, Andrew C , Abboud, Donna M , Gala, Khushboo , Vargas, Eric J. , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy | June 26, 2023 | Volume: 55 | Issue: 11 | Pages: 1028-1034

10.1055/a-2117-6274 | PMID 37364600 Get It

Background The primary obesity surgery endoluminal 2.0 (POSE 2.0) procedure involves full-thickness gastric body plications to narrow the stomach using durable suture anchor pairs. We evaluated POSE 2.0 as a treatment strategy for nonalcoholic fatty liver disease (NAFLD) in patients with obesity. Methods Adults with obesity and NAFLD were prospectively allocated based on their preference to undergo POSE 2.0 with lifestyle modification or lifestyle modification alone (control). Primary end points were improvement in controlled attenuation parameter (CAP) and resolution of hepatic steatosis at 12 months. Secondary end points included %total body weight loss (%TBWL), change in serum measures of hepatic steatosis and insulin resistance, and procedure safety. Results 42 adult patients were included (20 in the POSE 2.0 arm and 22 in the control arm). At 12 months, POSE 2.0 significantly improved CAP, whereas lifestyle modification alone did not (P < 0.001 for POSE 2.0; P = 0.24 for control). Similarly, both resolution of steatosis and %TBWL were significantly higher with POSE 2.0 than with control at 12 months. Compared with controls, POSE 2.0 significantly improved liver enzymes, hepatic steatosis index, and aspartate aminotransferase to platelet ratio at 12 months. There were no serious adverse events. Conclusion POSE 2.0 was effective for NAFLD in patients with obesity, with good durability and safety profile.
Abstract 15279: Ablation or Antiarrhythmic Drugs Alone in the Treatment of Ventricular Storm
Zhong, Qiaonan , Deshmukh, Abhishek , Bennett, Courtney

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.15279 Get It

Introduction: Ventricular storms are managed with a combination of antiarrhythmic drugs (AAD) and ablation therapy. This study examines outcomes in patients who required cardiac intensive care unit (CICU) admission for ventricular storms. Methods: A retrospective cohort study was conducted of 200 random adult patients who admitted to the CICU at Mayo Clinic Rochester in 2016-2017 for ventricular storm. Continuous variables were analyzed with the Mann-Whitney U test. Categorical variables were analyzed with Fisher's exact test. Results: Of the 200 patients, 33 (16.5%) patients underwent ablation and AAD therapy for ventricular arrhythmias; 167 underwent AAD therapy alone. The patients in the ablation group were significantly younger (median of 60.3 vs. 72.7, U=1570, p&lt;.001), had a lower Charlson Comorbidity Index (3.56 vs. 5.21, U=1916, p=.005), and a higher BMI (31.6 vs. 28.2, U=2028, p=.032). There was no difference in sex and race (white vs. non-white) between the two groups. The patients in the ablation groups had a significantly lower in-hospital mortality (0% vs. 20%, p=.001) and higher 1-year survival (91% vs. 63%, p=.001). There was no difference in length of stay in the CICU, length of stay in the hospital, or rate of hospital readmission within one year of discharge. Conclusions: Our study indicates that critically ill patients who undergo ablation and AAD for ventricular arrhythmias have decreased mortality compared to patients who underwent AAD therapy alone. More research is needed to elucidate whether this survival benefit is secondary to differences in treatment or baseline comorbidities in the two groups. Table 1: Characteristics and outcomes of patients undergoing ventricular storm treatment. Data is reported either as median or number of occurrences (%). Antiarrhythmic drug (AAD), Charlson Comorbidity Index (CCI), Body Mass Index (BMI), Cardiac Intensive Care Unit (CICU), Length of Stay in days (LOS). * Significance with p values &lt; .05
Through-the-scope suture closure of nonampullary duodenal endoscopic mucosal resection defects: a retrospective multicenter cohort study
Almario, Jose Antonio , Zhang, Linda Y. , Cohen, Jonathan , Haber, Gregory , Ramberan, Hemchand, Gordon, Stuart R. , Adler, Jeffrey M., Pohl, Heiko , Schlachterman, Alexander , Qumseya, Bashar , Kumta, Nikhil A. , Kim, Raymond , Aihara, Hiroyuki , Shrigiriwar, Apurva , Ngamruengphong, Saowanee , Khashab, Mouen A., group, Working, Storm, Andrew C , Canakis, Andrew , Storm, Andrew C. , Kumar, Anand , Singh, Shailendra , Draganov, Peter V. , Canakis, Andrew , Khashab, Mouen A. , group, Working

Mayo Clinic

Endoscopy | May 19, 2023 | Volume: 55 | Issue: 09 | Pages: 865-870

10.1055/a-2077-4832 | PMID 37207666 Get It

Background Delayed bleeding is among the most common adverse events associated with endoscopic mucosal resection (EMR) of nonampullary duodenal polyps. We evaluated the rate of delayed bleeding and complete defect closure using a novel through-the-scope (TTS) suturing system for the closure of duodenal EMR defects. Methods We reviewed the electronic medical records of patients who underwent EMR for nonampullary duodenal polyps of ≥ 10 mm and prophylactic defect closure with TTS suturing between March 2021 and May 2022 at centers in the USA. We evaluated the rates of delayed bleeding and complete defect closure. Results 36 nonconsecutive patients (61 % women; mean [SD] age, 65 [12] years) underwent EMR of ≥ 10-mm duodenal polyps followed by attempted defect closure with TTS suturing. The mean (SD) lesion size was 29 (19) mm, defect size was 37 (25) mm; eight polyps (22 %) involved > 50 % of the lumen circumference. Complete closure was achieved in all cases (78 % with TTS suturing alone), using a median of one TTS suturing kit. There were no cases of delayed bleeding and no adverse events attributed to application of the TTS suturing device. Conclusion Prophylactic closure of nonampullary duodenal EMR defects using TTS suturing resulted in a high rate of complete closure and no delayed bleeding events.
Long‐term quality of life after treatment in sinonasal malignancy: A prospective, multicenter study
Maoz, Sabrina L. , Hwang, Peter H. , Fleseriu, Cara M. , Chan, Erik P., Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Lazor, Jillian W. , Nabavizadeh, Ali , Adappa, Nithin D. , Patel, Zara M. , Smith, Timothy L. , Storm, Phillip B. , Suh, Jeffrey D. , Wang, Marilene B. , Sim, Myung‐Shin , Wang, Eric W , Choby, Garret , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Beswick, Daniel , Hwang, Peter H , Maoz, Sabrina L , Choby, Garret , Chan, Erik, Adappa, Nithin D. , Geltzeiler, Mathew , Le, Christopher H. , Abuzeid, Waleed M. , Lee, Jivianne K., Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Beswick, Daniel M.

Mayo Clinic

International Forum of Allergy & Rhinology | April 21, 2023 | Volume: 13 | Issue: 11 | Pages: 2030-2042

10.1002/alr.23171 | PMID 37082883 Get It

AbstractBackgroundQuality of life (QOL) for individuals with sinonasal malignancy (SNM) is significantly under‐studied, yet it is critical for counseling and may impact treatment. In this study we evaluated how patient, treatment, and disease factors impact sinonasal‐specific and generalized QOL using validated metrics in a large cohort over a 5‐year posttreatment time frame.MethodsPatients with SNM who underwent definitive treatment with curative intent were enrolled in a prospective, multisite, longitudinal observational study. QOL was assessed using the 22‐item Sino‐Nasal Outcome Test (SNOT‐22) and University of Washington Quality of Life Questionnaire (UWQOL) instruments at pretreatment baseline and multiple follow‐ups through 5 years posttreatment. Multivariable modeling was used to determine demographic, disease, and treatment factors associated with disease‐specific and generalized physical and social/emotional function QOL.ResultsOne hundred ninety‐four patients with SNM were analyzed. All QOL indices were impaired at pretreatment baseline and improved after treatment. SNOT‐22 scores improved 3 months and UWQOL scores improved 6 to 9 months posttreatment. Patients who underwent open compared with endoscopic tumor resection had worse generalized QOL (p < 0.001), adjusted for factors including T stage. Pterygopalatine fossa (PPF) involvement was associated with worse QOL (SNOT‐22, p < 0.001; UWQOL Physical dimension, p = 0.02). Adjuvant radiation was associated with worse disease‐specific QOL (p = 0.03). Neck dissection was associated with worse generalized physical function QOL (p = 0.01). Positive margins were associated with worse generalized social/emotional function QOL (p = 0.01).ConclusionDisease‐specific and generalized QOL is impaired at baseline in patients with SNM and improves after treatment. Endoscopic resection is associated with better QOL. PPF involvement, adjuvant radiation, neck dissection, and positive margins were associated with worse QOL posttreatment.
Safety of endoscopic ultrasound-guided tissue acquisition with uninterrupted direct oral anticoagulation in a swine model
Paredes, Ana García García de , Hartley, Christopher , Hernández-Lara, Ariosto H. , Pruthi, Rajiv K. , Gleeson, Ferga C. , Levy, Michael J. , Rajan, Elizabeth , Garcia Garcia de Paredes, Ana , AbiMansour, Jad P. , Valls, Eric J. Vargas, Hartley, Christopher P , Vargas, Eric J. , Graham, Rondell P. , Storm, Andrew C.

Mayo Clinic

Endoscopy International Open | January 19, 2023 | Volume: 11 | Issue: 04 | Pages: E413-E418

10.1055/a-2016-0160 | PMID 37124710 Get It

Abstract Background and study aims The risk of bleeding with endoscopic ultrasound-guided tissue acquisition (EUS-TA) in patients on uninterrupted antithrombotic agents is unknown. This study aimed to assess the safety of EUS-TA without discontinuing direct oral anticoagulants. Methods Twenty pigs were randomized (1:1) to oral apixaban or placebo. Treatment was administered for 3 days before and 3 days after EUS-TA of the pancreas. Primary endpoint was occurrence of clinically significant bleeding events (CSBEs), defined as a composite outcome of drop in hemoglobin ≥ 2 g/dL and evidence of intraprocedural or post-procedure bleeding. Secondary outcome was cytopathological adequacy of acquired specimens. Endoscopists and pathologists were blinded to the treatment arm. Results Total of 80 tissue samples were obtained. CSBE occurred in one animal with apixaban levels above the upper limit (P = 1). Intraprocedural bleeding occurred in five animals (25 %), four of which from the apixaban group. Hematoma at necropsy was found in 10 animals (50 %), six of which were on apixaban. Median drop in hemoglobin was similar in both groups. Adequacy of specimens for cytology and pathology evaluation was confirmed in 20 of 20 and 19 of 20 animals, respectively. Conclusions In this pilot preclinical trial, EUS-TA under apixaban showed a trend toward higher minor bleeding events but did not increase CSBE or prevent adequate cytopathological evaluation.
Weathering the storm: a single-institution experience with paroxysmal sympathetic hyperactivity after brain tumor resection in pediatric patients
Bouchal, Samantha M. , Naylor, Ryan M. , Bouchal, Samantha M , Daniels, David J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | January 6, 2023 | Volume: 31 | Issue: 4 | Pages: 282-289

10.3171/2022.12.peds22369 | PMID 36609373 Get It

OBJECTIVE Paroxysmal sympathetic hyperactivity (PSH) is a complication of severe traumatic or hypoxic brain injury characterized by transient episodes of tachycardia, tachypnea, hypertension, hyperthermia, diaphoresis, and/or dystonic posturing. Posttraumatic "sympathetic storms" are associated with poor outcomes. PSH rarely occurs after brain tumor resection in pediatric patients; only 4 cases have been published since 1929. Thus, the authors sought to report their experience with postcraniotomy PSH in pediatric brain tumor patients. METHODS A retrospective study of patients younger than 18 years of age who underwent craniotomy for brain tumor resection at a single center by a single surgeon over a 7-year period was performed. A clinical diagnosis of postoperative PSH was recorded. Recorded outcomes included the interval between surgery and initiation of cytotoxic therapy, need for long-term CSF diversion, length of hospital stay, and survival. RESULTS Of the 150 patients who were included for analysis, 4 patients were diagnosed with postoperative PSH for an overall occurrence of 2.7%. PSH patients were younger than non-PSH patients (1.8 ± 0.4 years vs 9.2 ± 5.3 years, p = 0.010) and tended to have intraventricular tumors close to the thalamus, basal ganglia, and/or brainstem. PSH patients experienced longer hospital admissions (44.3 ± 23.4 days vs 6.8 ± 9.4 days, p = 0.001), a shorter interval between surgery and initiation of cytotoxic cancer-directed therapy (14.3 ± 8.0 days vs 90.7 days ± 232.9 days, p = 0.011), and increased need for long-term CSF diversion compared with non-PSH patients (75% vs 25%, p = 0.005). At the last follow-up, 50% of PSH patients had died compared with 13% of non-PSH patients (p = 0.094). CONCLUSIONS PSH is a rare postoperative complication that may affect young children with periventricular tumors and is associated with poorer clinical outcomes. Increasing awareness of this condition is vital to improving patient outcomes.
Endoscopic Ultrasound-guided Transluminal Gallbladder Drainage in Patients With Acute Cholecystitis
Irani, Shayan , Sharma, Neil , Chahal, Prabhleen , Baron, Todd H. , Kozarek, Richard A. , Peetermans, Joyce , McMullen, Edmund, Ho, Evelyne, Merwe, Van der , Storm, Andrew C. , Shah, Raj J. , Willingham, Field F. , Swanström, Lee L. , Shlomovitz, Eran

Mayo Clinic

Annals of Surgery | December 20, 2022 | Volume: 278 | Issue: 3 | Pages: e556-e562

10.1097/sla.0000000000005784 | PMID 36537290 Get It

Objective: To evaluate the safety and efficacy of endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) using a lumen-apposing metal stent (LAMS). Background: For patients with acute cholecystitis who are poor surgical candidates, EUS-GBD using a LAMS is an important treatment alternative to percutaneous gallbladder drainage. Methods: We conducted a regulatory-compliant, prospective multicenter trial at 7 tertiary referral centers in the United States of America and Belgium. Thirty consecutive patients with mild or moderate acute cholecystitis who were not candidates for cholecystectomy were enrolled between September 2019 and August 2021. Eligible patients had a LAMS placed transmurally with 30 to 60-day indwell if removal was clinically indicated, and 30-day follow-up post-LAMS removal. Endpoints included days until acute cholecystitis resolution, reintervention rate, acute cholecystitis recurrence rate, and procedure-related adverse events (AEs). Results: Technical success was 93.3% (28/30) for LAMS placement and 100% for LAMS removal in 19 patients for whom removal was attempted. Five (16.7%) patients required reintervention. Mean time to acute cholecystitis resolution was 1.6±1.5 days. Acute cholecystitis symptoms recurred in 10.0% (3/30) after LAMS removal. Five (16.7%) patients died from unrelated causes. Procedure-related AEs were reported to the FDA in 30.0% (9/30) of patients, including one fatal event 21 days after LAMS removal; however, no AEs were causally related to the LAMS. Conclusions: For selected patients with acute cholecystitis who are at elevated surgical risk, EUS-GBD with LAMS is an alternative to percutaneous gallbladder drainage. It has high technical and clinical success, with low recurrence and an acceptable AE rate. Clinicaltrials.gov, Number: NCT03767881.